Morning sickness drug reintroduced to US


The US Food and Drug Administration (FDA) has approved a drug for morning sickness, 30 years after it was originally removed from the market.

Diclegis (doxylamine succinate and pyridoxine hydrochloride), contains the same active ingredients as Benedictin, which was produced by Merrel Dow and withdrawn from the market in 1983 after a string of lawsuits claiming it caused birth defects.

Rather than fight the litigations, Merrel Dow voluntarily withdrew the product. However, Canadian company Duchesnay continued to market the drug in Canada, under the name Diclectin. Large scale studies have shown the drug to be safe for both mothers and foetuses, so Duchesnay has now decided to expand into the US by applying for approval of its long-release version.

The drug has been approved for use by pregnant women whose morning sickness cannot be controlled through dietary means, such as by eating smaller meals of bland food throughout the day.


Related Content

Chemistry World podcast - January 2014

15 January 2014 Podcast | Monthly

news image

This month, we examine the controversy surrounding the Turin shroud and explore the history of crystallography

Business roundup

26 February 2008 Business

news image

Industry news

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Toxicologists enter the fray on endocrine disruptors

29 July 2013 News and Analysis

news image

Open letter urges the European commission to consult with the scientific community before enacting any regulation